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Abstract
Background: Breast cancer is worldwide the second most common type of cancer after lung cancer. Plasma
proteome profiling may have a higher chance to identify protein changes between plasma samples such as
normal and breast cancer tissues. Breast cancer cell lines have long been used by researches as model system for
identifying protein biomarkers. A comparison of the set of proteins which change in plasma with previously
published findings from proteomic analysis of human breast cancer cell lines may identify with a higher
confidence a subset of candidate protein biomarker.
Results: In this study, we analyzed a liquid chromatography (LC) coupled tandem mass spectrometry (MS/MS)
proteomics dataset from plasma samples of 40 healthy women and 40 women diagnosed with breast cancer.
Using a two-sample t-statistics and permutation procedure, we identified 254 statistically significant, differentially
expressed proteins, among which 208 are over-expressed and 46 are under-expressed in breast cancer plasma. We
validated this result against previously published proteomic results of human breast cancer cell lines and signaling
pathways to derive 25 candidate protein biomarkers in a panel. Using the pathway analysis, we observed that the
25 “activated” plasma proteins were present in several cancer pathways, including ‘Complement and coagulation
cascades’, ‘Regulation of actin cytoskeleton’, and ‘Focal adhesion’, and match well with previously reported studies.
Additional gene ontology analysis of the 25 proteins also showed that cellular metabolic process and response to
external stimulus (especially proteolysis and acute inflammatory response) were enriched functional annotations of
the proteins identified in the breast cancer plasma samples. By cross-validation using two additional proteomics
studies, we obtained 86% and 83% similarities in pathway-protein matrix between the first study and the two
testing studies, which is much better than the similarity we measured with proteins.
Conclusions: We presented a ‘systems biology’ method to identify, characterize, analyze and validate panel
biomarkers in breast cancer proteomics data, which includes 1) t statistics and permutation process, 2) network,
pathway and function annotation analysis, and 3) cross-validation of multiple studies. Our results showed that the
systems biology approach is essential to the understanding molecular mechanisms of panel protein biomarkers.
Background
Breast cancer is worldwide the second most common
type of cancer after lung cancer. According to the
American Cancer Society, approximately 192,370
women in the US will be diagnosed with breast cancer
in 2010, and about 40,170 women will die from the
disease.
Molecular biomarkers have become increasingly
important clinical tools for cancer screening, diagnosis,
treatment customizations. There has been an increasing
number of research reports on developing breast cancer
biomarkers, especially in blood [1]. Many molecular bio-
markers with expression level changes have been identi-
fied in breast cancer tissue samples or blood, for
example, HER2 [2], PNCA [3], Lipofilin B [4], Cyclin D1
[5], CEACAM6 [6], Osteopontin-c [7], RCP [8], and
FOXA1 [9].
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achieved using functional genomics studies of estab-
lished breast cancer cell lines [10] [11] [12] [13] [14].
Cell lines are widely used in many aspects of laboratory
research and particularly as in vitro models in cancer
research. They have a number of advantages, including
being easy to access and offering “clean” results with
statistically significant signals. However, human systems
are quite complex [15], and many candidate biomarkers
discovered in cell lines do not readily transfer to human
tissues or blood, in which clinical testing will be per-
formed. Therefore, profiling human plasma using pro-
teomics techniques offers an appealing alternative to cell
lines or tissue biospecimens in developing protein bio-
markers [16], although the debate over this issue is
heated [17].
The question whether protein biomarker identified in
blood can be valuable rests primarily on our ability to
address the complexity associated with the human
plasma proteome. The inherent presence of measure-
ment noise, inconsistencies due to individual differ-
ences, and sample biases of the plasma proteomics
approach have been reported [18]. However, our recent
studies also showed, by collecting plasma proteomics
into a common proteomics data repository, the HIP2
database [19], we could start to reduce the perceived
coverage biases for plasma proteomics, and explore a
promising goldmine of candidate cancer biomarkers
and drug targets [20]. In addition, bioinformatics and
systems biology techniques can help reduce this com-
plexity significantly. For example, one can use plasma
proteomics to derive breast cancer candidate protein
markers and then use gene expression mapping to vali-
date candidate protein biomarkers that are known to
be secreted. One can also use advanced visualization
or network biology techniques such as [21] [22]to
model and monitor global patterns of changes in pro-
teomics, instead of candidate biomarkers at the indivi-
dual protein level [23].
In this paper, we adopted a systems biology approach
to the study of panel protein biomarker discovery in
breast cancer using plasma. For polygenic diseases
such as breast cancer and a complex detection plat-
form such as human blood, we recognize that a single
protein biomarker approach using “expressions” will
not suffice for the high performance requirement of
breast cancer screening and diagnosis. Therefore, by
enlisting multiple proteins as analytes that are mechan-
istically linked to breast cancer pathways or functional
networks, we believe that the chance of success would
be higher than the simpler conventional single-marker
approach.
Our computational analysis involves several steps.
First, we used a t-statistics and permutation procedure
to identify protein biomarker candidates that are signifi-
cantly differentially detected among different individual
plasma samples between the case and the control for
breast cancer. Second, we performed an extensive litera-
ture curation to determine the constituents of the
plasma protein biomarker panel. Third, we performed
gene ontology analysis and pathway analysis to validate
the list to reveal the intricate breast cancer related
molecular mechanism that exists among the protein bio-
markers on the panel. Fourth and last, we validated our
results using two independent publicly-available breast
cancer proteomics datasets derived from other groups.
Our results showed that such an integrative systems
approach is essential to development and validation of
panel protein biomarkers that may withstand rigorous
testing for the future steps.
Results
Normality test
The plasma proteome profiling dataset in Study A con-
tains 4832 peptides, two states (health and breast can-
cer) and 40 samples each state. Q-Q plot and one
sample Kolmogorov-Smirnov test in Figure 1 showed
that the log2 transformation intensity values for all 4832
peptides from 40 health women are not normally dis-
tributed (One-sample Kolmogorov-Smirnov test, D =
0.0419, p-value < 2.2e-16). We also found the intensity
values from 40 women diagnosed with cancer in Study
A, women diagnosed with cancer from Study B and C,
and healthy women form Study B and C are likewise
not normally distributed.
Figure 1 Q-Q Plot for Data from 40 Health women in Study A
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4832 peptides in the Study A were mapped to 1422 pro-
teins by searching against the IPI database. Using a t
statistics and permutation process described in the
Methods section and setting a p-value cut-off of 0.001
after initial ANOVA analysis of mass spectra data, we
identified 254 statistically significant differentially
expressed proteins (PFER=1.422, FDR=0.0056), among
which 208 are over-expressed and 46 are under-
expressed in breast cancer plasma. Compared to the
results of traditional statistical testing (PFER=2.5596,
FDR=0.01), our results show that the coupled statistical
process outperforms the sensitivity of a parametric tra-
ditional statistical test that requires strong and some-
times untenable data assumptions since it is non-
parametric and requires no assumption about the distri-
bution under the null hypothesis.
A comparison of the set of 254 proteins with pub-
lished findings from proteomic analysis of human breast
cancer cell lines yielded 25 differentially expressed pro-
teins in common. Top networks were identified by
using Ingenuity Pathway Analysis (Table 1, and Figure
2). Figures 3a and 3b quantified the biological signifi-
cance of gene ontology biological processes
Cross-validation of candidate biomarkers
In order to validate our computational results, the same
methods and procedures we used in Study A were
applied to Studies B and C. As shown in the Venn dia-
gram (Figure 4), 20 candidate protein biomarkers were
identified in Study B, of which 13 were found in com-
mon with study A, and 25 candidate protein biomarkers
were identified in Study C, of which 13 were found in
common with study A. The similarity measurements
with the protein method are 40% for biomarker sets
from Study A and Study B and 35% for biomarker sets
from Study A and Study C.
The pathway-protein association matrix is shown in
the Additional file 1. The top three pathways: ‘Comple-
ment and coagulation cascades’, ‘Regulation of actin
cytoskeleton’,a n d‘Focal adhesion’ are ranked top in all
three studies (Figure 5). The similarity measurements
with the pathway-protein matrix method are 86% for
biomarker sets from Study A and Study B and 83% for
biomarker sets from Study A and Study C.
Using Ingenuity Pathway Analysis and DAVID GO
analysis, we also found that biomarkers identified from
the Study B and Study C have similar network and func-
tion as the 25 candidate protein biomarkers identified
from study A.
From the cross-validation offered by our ‘systems biol-
ogy’ approach, we found similar pathway, network and
function in those biomarkers identified from the three
studies. The systems biology approach helps to unravel
the intricate pathways, networks and functional contexts
in which genes or proteins function and is essential to
the understanding molecular mechanisms of panel pro-
tein biomarkers.
Discussion
Permutation test
Most of protein identification methods were based on
fold change. Fold change is easy to use and implement,
fast and works with any number of arrays, but it does
not take the variability of a protein into account and
offers no significance measure of p-value. In this paper,
we used a t-statistics to calculate the initial p-value that
can takes the variance into account.
Theoretically, the t-test can be used even if the sample
sizes are very small (e.g., as small as 10; some research-
ers claim that even smaller samples are manageable), as
long as the variables are normally distributed within
each group and the variation of scores in the two groups
is not reliably different. If populations from which data
to be analyzed by a t-test were sampled violate one or
more of the t-test assumptions, the results from the ana-
lysis may be incorrect or misleading. For example, if the
assumption of independence is violated, then the two-
sample unpaired t-test is simply not appropriate. If the
assumption of normality for the t-test is violated, or out-
liers are present, then the t-test may not be the most
powerful test available. However, our plasma protein
profiling shows no normal distribution (Figure 1). In
order to detect a true difference between health and
control samples, a permutation process was used, and
should be reliable regardless of whether or not the sam-
ple distribution is known.
Our results showed that the permutation test was very
similar to the t-test in its p-value estimate. The t-test is
a parametric test and the permutation process is non-
parametric. By using the permutation test we made no
Table 1 Top Networks Involved
Primary Network Functions Computed Score Molecules in Network
Endocrine System Disorders, Metabolic Dis-ease, Antigen Presentation 41 17
Cell-To-Cell Signaling and Interaction, Tissue Development, Hematological Disease 13 7
Gene Expression, Cancer, Dermatological Diseases and Conditions 2 1
Cardiac Arteriopathy, Cardiovascular Disease, Genetic Disorder 2 1
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hypothesis. Usually, the assumptions in the null hypoth-
esis are weakened, and it becomes harder to reject. The
permutation process rivals the sensitivity of a parametric
t-test assuming equal variances.
To compare the power of the t-test and permutation
test, that is, how likely they are to reject the null
hypothesis when an alternate hypothesis is true, we
assume specific distributions for the alternate hypoth-
esis. For the t-test, the most natural alternate hypothesis
is that the two samples are from different normal distri-
butions. For large samples, it has been shown that the
power of the permutation process using the difference
in sample means is equal to the t-test for normally dis-
tributed alternates.
We used quantitative method to compare the results of
ttperm function in the Category package of the R lan-
guage using the method described in the method section.
All 16 biomarkers identified using ttperm function are
among the 25 panel biomarkers identified by our permu-
tation test method in Study A. 13 of them are identified
in Study C. Comparing them with the 20 candidate pro-
tein biomarkers we identified from study B, there are
only 7 in common. But the remaining 9 proteins not
identified by our permutation method are also not cho-
sen as candidate protein biomarkers by previous findings
using breast cell lines [10] [13] [14] [24]. Gene ontology
analysis using the 16 biomarkers showed that response to
external stimulus was annotated, but cellular metabolic
process was not, and acute inflammatory response was
annotated but proteolysis not. The cellular metabolic
process (proteolysis) annotated by our permutation
method was reported to be related to cancer progression
[11]. All the results show that our permutation test
method is highly robust to the equality of the variances,
regardless of whether the same sizes are similar and car-
ries more conviction than the other permutation test
which doesn’t consider the affect of variance inequality.
Figure 2 The 25 Proteins Are Involved in an Endocrine System Disorders Network. Red stands for over-expressed and green for under-
expressed
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A total of 416 peptides were identified from analyzing
the plasma protein profiling from 40 women diagnosed
with breast cancer and from 40 healthy women using
the permutation test, corresponding to 254 unique UNI-
PROT protein names. A comparison of the 254 proteins
with previously published findings from proteomic ana-
lysis of human breast cancer cell lines yielded 25 candi-
date protein biomarkers. The 25 proteins were
categorized by their interactive pathway, network and
annotated biological process on Gene Ontology.
An interesting finding from Pathway Analysis is that
those top networks shown in the Table 1 and Figure 1,
especially the top 1 network (Endocrine System Disor-
ders, Metabolic Disease, Antigen Presentation) and top
3 pathways (‘Complement and coagulation cascades’,
‘Regulation of actin cytoskeleton’,a n d‘Focal adhesion’),
are validated by our B and C dataset results, and are
similar to previously reported works [25] [26] [27] [28].
For example, Ana-Teresa et al. studied 12 candidate
genes that are implicated in the etiology of breast cancer
and found these genes are functionally involved in com-
plement and coagulation cascades pathway [29]. Carol
et al. reported that the cell migration in breast cancer
lines can also be regulated by actin cytoskeleton
dynamics [30]. And Michael et al. reported that
increased focal adhesion kinase expression correlates
with TGF-b1-mediated activation of p38 MAPK in
metastatic human breast cancer cells and concluded
that focal adhesion is essential in mediating oncogenic
signaling by transforming growth factor (TGF)-b [31].
Another interesting finding from our Gene Ontology
work is the role of cellular metabolic process and
response to external stimulus (especially proteolysis and
acute inflammatory response) in Figure 3a and 3b in
breast cancer was also reported by other authors. For
example, cancer, like other diseases, is accompanied by
strong metabolic disorders [11]. And It was also
Figure 3 Gene Ontology Biological Processes Enrichment Analysis for 25 Protein Biomarkers.
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microbial infections, ultraviolet radiation, and chemical
stress from heavy metals and pesticides affect the pro-
gression of breast cancer [32].
Conclusions
254 statistically significantly differentially expressed
proteins between 40 healthy women and 40 women
diagnosed with breast cancer were identified from
initial LC-MS/MS experiments using a t statistics and
permutation process which is useful in independent
two-sample hypothesis testing. Top breast cancer acti-
vated networks and pathways were identified through
systems biology approach. 25 candidate protein bio-
markers were validated from the pathway/network ana-
lysis, literature curation from previous published
findings in breast cell lines, and two additional studies.
Gene ontology analysis confirmed that cellular meta-
bolic process and response to external stimulus (espe-
cially proteolysis and acute inflammatory response)
were enriched in the 25 protein biomarker panel. Path-
way analysis identified three top enriched pathways:
‘Complement and coagulation cascades’, ‘Regulation of
actin cytoskeleton’,a n d‘Focal adhesion’. Our approach
integrating computing, basic biomedical research, and
clinical applications promises to be able to “translate”
between scientific innovations and clinical diagnostic
needs for breast cancer. Assay Development and
Clinical Trials for Panel Biomarker from breast cancer
patients are needed to assess which of the identified
proteins may have diagnostic utility.
Methods
Biomarker identification and characterization holds great
promise for more precise diagnoses and for tailored
therapies. The heterogeneity of human cancers and
unmet medical needs in these diseases provides a com-
pelling argument to focus biomarker development in
cancer. Mass spectrometry based proteomics approaches
have provided insight into biomarkers of cancer and
other diseases with femtomole sensitivity and high ana-
lytical precision. The schema of methods in this paper is
shown in the following Figure 6.
First, proteins were prepared and subjected to LC/MS/
MS analysis. Samples were run on a Surveyor HPLC
(ThermoFinnigan) with a C18 microbore column (Zor-
bax 300SBC18, 1 mm × 5 cm). All tryptic peptides (100
μLo r2 0μg) were injected onto the column in random
order. Peptides were eluted with a linear gradient from
5% to 45% acetonitrile developed over 120 min at a flow
rate of 50 μL/min, eluant was introduced into a Ther-
moFinnigan LTQ linear ion-trap mass spectrometer.
The data were collected in the “triple-play” mode (MS
scan, Zoom scan, and MS/MS scan). Next, a permuta-
tion procedure was used to determine the p-value. The
80 samples for each peptide were permuted 100,000
times and the complete set of t-tests between the first
40 values and the last 40 values, was performed for each
permutation. Next, 4 previously published proteomic
studies of breast cancer cell lines were used for compar-
ison. Then, top networks and pathways were identified
with Ingenuity Pathways analysis, KEGG and HPD path-
way databases. And Level 2 and 5 of biological process
in gene ontology were mainly studied. And then, two
testing cancer dataset were used to validate the result.
Last, assay development and clinical trials for panel bio-
markers are planned for the future.
Database
Plasma protein profiles were collected in three batches,
which we refer to as Studies A, B and C. All 3 of these
studies were processed in the same laboratory but at dif-
ferent times. Each sample was analyzed in a single batch
by mass spectrometry. In both Studies A and B, 80
plasma samples were collected (40 samples collected
from women with breast cancer and 40 from healthy
volunteer woman who served as controls). In Study C,
40 plasma samples were collected (20 samples collected
from women with breast cancer and 20 from healthy
volunteer woman who served as controls). The demo-
graphy and clinical distribution of breast cancer stages/
subtypes for study A, B and C are comparable, although
Figure 4 Venn Diagram of Markers Venn diagram indicating the
degree of overlap among the markers identified from three data
sets: Study A, B and C.
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ler than Study A and B.
We compared our results with 4 previously published
proteomic studies of breast cancer cell lines. Their
methods and results presented in peer reviewed journals
[10, 12-14] have established a high reliability. A total of
3085 protein biomarkers were identified from the five
breast cell lines, MCF-10A, BT474, MDA-MB-468, MD-
MB-468, and T47D/MCF7 in their papers.
Protein identification and quantification
For protein identification, Tryptic peptides were analyzed
using Thermo-Finnigan linear ios-trap mass spectro-
meter (LTQ) coupled with a HPLC system. Peptides were
eluted with a gradient from 5 to 45% Acetonitrile devel-
oped over 120 minutes and data were collected in the tri-
ple-play mode (MS Scan, zoom scan, and MS/MS scan).
The acquired raw peak list data were generated by
XCalibur (version 2.0) using default parameters and
further analyzed by the label-free identification and quan-
titative algorithm using default parameters described by
Higgs et al [33]. MS database searches were performed
against the combined protein data set from International
Protein Index (IPI; version 3.60) and the non-redundant
NCBI-nr human protein database (updated 2009), which
totaled 22,180 protein records. Carious data processing
filters for protein identification were applied to control
false-discovery rate at below 5% levels.
For protein quantification, first, all extracted ion chro-
matograms (XICs) were aligned by retention time. Each
aligned peak were matched by precursor ion, charge state,
fragment ions from MS/MS data, and retention time
within a one-minute window. Then, after alignment, the
area-under-the-curve (AUC) for each individually aligned
peak from each sample was measured, normalized, and
compared for relative abundance—all as described in [33].
Figure 5 Heatmap of Pathway-Protein Frequency Count Matrix Vertical axis represents pathway and horizontal axis represents studies. Each
cell corresponds to the count of represented proteins in pathway for the corresponding Study.
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ANOVA (Analysis of Variance) was used to quantify pro-
tein intensities. In principle, the linear mixed model con-
siders three types of effects when deriving protein
intensities based on weighted average of quantile-normal-
ized peptide intensities: 1) group effect, which refers to the
fixed non-random effects caused by the experimental con-
ditions or treatments that are being compared; 2) sample
effect, which refers to the random effects (including those
arising from sample preparations) from individual biologi-
cal samples within a group; 3) replicate effect, which refers
to the random effects from replicate injections from the
same sample preparation.
“Systems biology” analysis
We applied a “systems biology” approach to the study of
panel biomarker discovery problem in breast cancer
proteomics data study in this study. Our strategies for
analyzing potentially noisy proteomics data set are
three-fold. First, we used a t-statistics and permutation
procedures to calculate p-value for proteins changed in
all samples, instead of fold change or t-test for a given
sample that were commonly used in previous studies.
This allowed us to better filter the proteomics results.
Second, we used extensive literature curation to focus
only on breast cancer relevant differentially expressed
proteins. This literature curation step allowed us to con-
centrate on breast cancer relevant signals, with generally
noisy proteomics data sets. Third, we used gene ontol-
ogy analysis and pathway analysis to identify and vali-
date correlated changes due to cancer cell signaling that
may, individually, elude the detection.
T statistics and permutation process
Our test statistic for study A and B is a mean of 40
values (protein intensities in health samples) minus the
mean of another 40 values (protein intensities in cancer
samples). For study C, the total sample number is 40
with 20 healthy samples and 20 cancer samples. A per-
mutation procedure was used to determine the p-value
for each protein, representing the chance of observing a
test statistic at least as large as the value actually
obtained. The 80 samples for each protein in Study A
and B (40 samples for Study C) were permuted 100000
times and the complete set of t-tests was performed for
each permutation. The permutation p-value for a parti-
cular protein is the proportion of the permutations in
which the permuted test statistic exceeds the observed
test statistic in absolute values. We chose a significance
level a=0.001 to select proteins where we estimated sig-
nificant differences in the health and cancer sampled.
The corresponding “per-family Type 1 error rate, PFER”,
that is, the expected number of false positives for such a
multiple test procedure is PFER = number of genes x
0.001. Alternatively, the nominal “false discovery rate,
FDR”, or expected proportion of false positive among
the genes declared differentially expressed, is FDR =
PFER/number of genes declared expressed.
Network and function annotation analysis
Ingenuity Pathway Analysis was used for building net-
work. DAVID database was used to study level 2 and 5
of biological process in gene ontology. Fisher’s exact test
is used to test the statistical significance for association
between the gene list with expression changes and the
function set [34].
Figure 6 Schema of Methods First, proteins were prepared and
subjected to LC/MS/MS analysis. Next, a permutation procedure was
used to determine the p-value. Next, 4 previously published
proteomic studies of breast cancer cell lines were used for
comparison. Then, top networks and pathways were identified with
Ingenuity Pathways analysis, KEGG and HPD pathway databases.
And Level 2 and 5 of biological process in gene ontology are
mainly studied. And then, two testing cancer dataset were used to
validate the result. Last, assay development and clinical trials for
panel biomarkers are planned for the future.
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Pathway comparison are performed using the following
databases: Kyoto Encyclopedia of Genes and Genomes
(http://www.genome.ad.jp/kegg/) [35]and HPD [36]. The
visualization for the pathway-protein association matrix
was created by Excel 2007 VBA.
Pathway-protein frequency count matrix
A pathway-protein frequency count matrix (PPFCM)
contains pathway on vertical axis and studies repre-
sented on horizontal axis. Each cell of PPFCM corre-
sponds to the count of represented proteins in pathway
for the corresponding Study.
Biomarker set similarity
We presented two approaches to measure the similarity
of biomarker sets: 1) protein method and 2) pathway-
protein matrix method.
The biomarker set similarity measure with the protein
method can be defined as the extent of overlaps, e.g.,
common number of biomarkers, shared between two
different biomarker sets. The set-set similarity score Si,j
is defined as
S
PP
PP
iN jN ij
ij
ij
,
||
||
, , == =


 11 (1)
where, N denotes total number of biomarker sets. Pi
and Pj denote two different biomarker sets, while |Pi|
and |Pj| are the numbers of biomarkers in these two
sets. Their intersection Pi ∩ Pj is the set of all biomar-
kers that appear in both Pi and Pj, while their union Pi
∪ Pj is a set of all biomarkers either appearing in the Pi
or in the Pj. Duplicates are eliminated in the intersection
set and union set.
The biomarker set similarity measure with the path-
way-protein matrix method can be defined as the cor-
rection coefficient of the number of represented
biomarkers in pathways for sets. The higher the correc-
tion coefficient is, the more similar the two sets. The
equation is expressed as
S
PP
PP
iN jN ij
ij
ij
,
||
||
, , == =


 11 (2)
where Corr is the Pearson correlation coefficient, Qi is
the biomarker numbers in pathways for set i, N denotes
total number of biomarker sets.
Additional file 1: Pathway-Protein Association MatrixPathway-
Protein Association Matrix
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